major facilitator superfamily domain containing 13B (pseudogene)Genealiases: []
Q-omics provides the consensus-scored MFSD13B profile across patient tissues and cancer cell-line models. MFSD13B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MFSD13B is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, MFSD13B RNA expression shows 20,378 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where MFSD13B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD13B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD13B survival associations across molecular data types. MFSD13B RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD13B RNA expression–survival associations across cancer types. High MFSD13B expression shows unfavorable associations in KIRC and LGG, but favorable associations in BLCA, THYM, HNSC and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for MFSD13B RNA expression.
This table summarizes MFSD13B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MFSD13B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD13B shows lower tumor expression in THCA and higher tumor expression in CHOL, KIRC and LIHC. The THCA box plot shows higher MFSD13B RNA expression in normal versus tumor tissue (log2 FC = −0.572, t-test p < 0.001).
This table shows molecular features associated with MFSD13B in patient tissues and cancer cell lines. In patient samples, MFSD13B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
